Erasca Q3 net loss $30.4M ($0.20/shr); cash $343.6M; first patient dosed in SEACRAFT-1

Erasca, Inc.

2023-Q3 EPS reported -$0.64

Net loss $30.4M ($0.20/shr) vs $35.5M ($0.29/shr) in Q3 2022; decrease in R&D expenses to $25.2M.
Cash, equivalents, and marketable securities $343.6M at Sep 30, 2023, down from $435.6M at Dec 31, 2022; runway into H2 2025.
First patient dosed in SEACRAFT-1 Phase 1b (naporafenib + trametinib) for RAS Q61X solid tumors in Aug 2023.
Upcoming catalysts: SEACRAFT-1 initial data H2 2024; SEACRAFT-2 Phase 3 start H1 2024; HERKULES-3 expansion data H2 2023-H1 2024.
THUNDERBBOLT-1 initial Phase 1 monotherapy data in recurrent GBM expected H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Erasca, Inc. reported the quarter ended September 30, 2023 results: net income Net loss was $30.4 million, or $(0.20) per basic and diluted share, EPS $(0.20) per basic and diluted share.

Period: the quarter ended September 30, 2023
Net income: Net loss was $30.4 million, or $(0.20) per basic and diluted share
EPS: $(0.20) per basic and diluted share
Result: reported results

Exact text from the filing

Erasca Reports Third Quarter 2023 Financial Results and Business Updates

View on SEC.gov

Browse all earnings releases →

Erasca, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-062003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.